Abstract | BACKGROUND: METHODS: SHR/NDmcr-cp rats were administered no medications (control) or low-dose olmesartan for 2 weeks and then either olmesartan at an increased dose, azelnidipine, or the hydrochlorothiazide for 3 weeks. We assessed oxidative stress in the kidney and aorta, and endothelial function. RESULTS: Urinary protein excretion was lower in all treated rats than in control rats. Oxidative stress caused by activation of NAD(P)H oxidase was observed in the glomeruli and aorta of control rats and was significantly suppressed in the olmesartan/ azelnidipine (Olm/Azl) groups. Combination therapy with olmesartan and hydrochlorothiazide (Olm/ HCTZ) however failed to suppress oxidative stress. The Olm/Azl groups maintained the endothelial surface layer in the glomeruli and protected endothelial function in the aorta. CONCLUSION:
|
Authors | Hajime Nagasu, Minoru Satoh, Daisuke Yorimitsu, Naruya Tomita, Tamaki Sasaki, Naoki Kashihara |
Journal | Kidney & blood pressure research
(Kidney Blood Press Res)
Vol. 34
Issue 2
Pg. 87-96
( 2011)
ISSN: 1423-0143 [Electronic] Switzerland |
PMID | 21273789
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 S. Karger AG, Basel. |
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Antihypertensive Agents
- Dihydropyridines
- Imidazoles
- Tetrazoles
- Hydrochlorothiazide
- Azetidinecarboxylic Acid
- olmesartan
- azelnidipine
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
- Animals
- Antihypertensive Agents
(therapeutic use)
- Azetidinecarboxylic Acid
(analogs & derivatives, therapeutic use)
- Dihydropyridines
(therapeutic use)
- Drug Therapy, Combination
- Hydrochlorothiazide
(therapeutic use)
- Imidazoles
(therapeutic use)
- Kidney Diseases
(prevention & control)
- Oxidative Stress
(drug effects)
- Rats
- Rats, Inbred SHR
- Tetrazoles
(therapeutic use)
- Vascular Diseases
(prevention & control)
|